Business Context and Reporting Period
This Form 6-K filing by XTL Biopharmaceuticals Ltd. (XTL) covers the month of January 2026, with a specific report date of January 13, 2026. XTL is an IP portfolio company traded on the Nasdaq Capital Market (XTLB) and the Tel Aviv Stock Exchange. The filing announces a strategic initiative to expand its asset portfolio through a proposed acquisition of NeuroNOS Ltd., a private biopharmaceutical company focused on treatments for Autism Spectrum Disorder (ASD), Alzheimer's disease, and brain cancers.
Key Financial Metrics and Transaction Terms
The filing does not provide historical revenue, profit, cash flow, or margin data for XTL. Financial details are limited to the proposed transaction structure and a concurrent financing plan:
- Proposed Acquisition Consideration:
- Equity: Issuance of American Depositary Shares (ADS) to grant Beyond Air, Inc. (XAIR) beneficial ownership of 19.99% of XTL's outstanding capital.
- Warrants: Issuance of three-year warrants to maintain the 19.99% beneficial ownership threshold.
- Up-Front Cash: US$1,000,000 payable within 60 days of closing.
- Clinical/Regulatory Milestones: Up to US$5,500,000 in aggregate, with an option for XTL to settle all obligations via a lump sum of US$4,000,000.
- Commercial Milestones: US$2,000,000 to US$12,500,000 based on cumulative net sales of the first NeuroNOS product.
- Private Placement Financing:
- Amount: Up to US$2,000,000 to fund the transaction and financial needs.
- Price: Approximately US$0.53 per ADS (a 20% discount to the closing bid price).
- Condition: Contingent upon the consummation of the acquisition transaction.
Material Changes and Strategic Developments
The primary material change is the entry into a binding Letter of Intent (LOI) to acquire 85% of NeuroNOS from XAIR. This represents a significant shift in XTL's strategy from holding an IP portfolio (including The Social Proxy Ltd. and hCDR1 licenses) to acquiring active clinical-stage assets. The transaction includes provisions for XAIR to exchange remaining NeuroNOS shares held by other shareholders for XTL ordinary shares. No historical financial comparisons are provided in this filing.
Guidance, Risks, and Contingencies
Outlook and Conditions: The transaction is subject to the negotiation of definitive agreements, mutual due diligence (legal, financial, clinical, IP, tax, regulatory), and shareholder approval. There is no assurance the transaction or the private placement will be consummated.
Risks and Contingencies:
- Transaction Failure: Risks include failure to negotiate definitive agreements or satisfy conditions precedent.
- Financing Risk: The private placement is conditional on the transaction closing; failure to secure funds could derail the deal.
- Integration and Operations: Risks related to managing joint ventures, unanticipated operating costs, and retaining key personnel.
- Market and Regulatory: Risks include adverse competition, changes in consumer behavior, and the ability to protect intellectual property.
- Lock-up Provisions: XAIR is restricted from selling more than 15% of the average daily trading volume of XTL ADSs until FDA approval of the first autism therapeutic product.
Investor Verification Checklist
- Verify the final terms of the definitive acquisition agreement, specifically the valuation implied by the 19.99% equity stake.
- Confirm the successful closing of the US$2,000,000 private placement and the identity of participating investors.
- Monitor the status of shareholder approvals required for both the transaction and the private placement.
- Review the clinical data and regulatory status of NeuroNOS's lead product candidates for ASD and other neurological conditions.
- Assess the dilution impact on existing shareholders resulting from the issuance of new ADSs and warrants.